Prestige Bio Presents Poster on Pancreatic Cancer Antibody Drug at US AACR

Prestige Biopharma announced on the 9th that it presented two posters, including the Phase 1/2a clinical trial of the pancreatic cancer antibody drug PBP1510, at the '2024 American Association for Cancer Research (AACR 2024)'.

AACR, one of the world's top three cancer conferences, provides a platform for discussing research results and the latest trends in anticancer drug development. Prestige Biopharma participated in AACR for the second consecutive year following last year. In the first poster presentation, the protocol and progress of the Phase 1/2a clinical trial of PBP1510, currently underway in five countries including the United States and Europe, were revealed for the first time.

PBP1510 is an antibody drug that treats pancreatic cancer by neutralizing the PAUF protein, which is overexpressed in more than 80% of pancreatic cancer patients. Currently, 10 out of 30 patients in the Phase 1 clinical trial have completed dosing. The presentation detailed the progress of the patients who completed dosing and the future clinical plans. As a fast-track designated antibody drug, if meaningful results are obtained in the Phase 1/2a trial, Prestige Biopharma plans to expedite commercialization by utilizing the Accelerated Approval and Priority Review systems.

The second presentation introduced the mechanism of action of the target protein CTHRC1 of PBP1710 in various solid tumors. PBP1710 is effective against tumor desmoplasia, where extracellular matrix components such as collagen excessively accumulate around cancer cells, forming connective tissue that hinders drug penetration, making it a candidate for development as a treatment for various solid tumors.

A Prestige Biopharma representative stated, “Local stakeholders highly evaluated the research results on PBP1510, an antibody drug that neutralizes PAUF to treat pancreatic cancer, as a meaningful advancement toward conquering pancreatic cancer, which currently has no targeted therapies.” He added, “We plan to expedite commercialization by leveraging various fast-track support programs from the U.S. FDA as soon as meaningful results are obtained from the ongoing Phase 1/2a clinical trial of PBP1510.”